Next generation antisense treatment for eye and inflammatory diseases as well as cancer.
Investors 2
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.04.2014 | - | $7.61M | - |
| 07.01.2014 | - | $17.7M | - |
Mentions in press and media 5
| Date | Title | Description |
| 04.05.2016 | Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma | — Preliminary Data Shows That ISTH0036 was Safe and Well Tolerated at Therapeutic Dose Levels —
MUNICH–(BUSINESS WIRE)–May 4, 2016–
Isarna Therapeutics, the leader in transforming growth factor beta (TGF-β) isoform targeted antisense therap... |
| 25.04.2014 | Isarna snags another $7.6M to advance its cancer immunotherapy | After shifting its focus to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $7.6 million to jump-start the development of some preclinical cancer candidates.
The latest financing comes on the heels of a $17.8 millio... |
| 24.04.2014 | Isarna Therapeutics Raises €5.5M in Equity Funding | Isarna Therapeutics GmbH, a Munich, Germany-based developer of TGF-β therapeutics, raised €5.5m (US$7.6m) in equity funding.
Backers included current investors AT NewTec, Global Asset Funds, and MIG Fonds.
The company intends to use the fun... |
| 24.04.2014 | Isarna Therapeutics Raises Euro 5.5 Million, Announces Elizabeth Czerepak Joining as CFO/CBO to Lead U.S. Site | MUNICH–(BUSINESS WIRE)–April 24, 2014–
Isarna Therapeutics GmbH, a leader in TGF-β therapeutics, today announced that it has raised Euro 5.5 million (US$ 7.6 million) in equity from its current investors including AT NewTec, Global Asset Fu... |
| 07.01.2014 | Isarna Therapeutics Raises €13M in Funding | Isarna Therapeutics GmbH, a Munich, Germany-based company that develops TGF-β inhibitors to fight cancer, raised €13m (US$17.8m) in equity.
Backers included new private investor AT NewTec and current investors MIG-managed funds.
The company... |
Reviews 0
